Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C27H30N4O4 |
| Molecular Weight | 474.5515 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(C=CC=C1)N2CCN(CC(O)COC3=CC=C(C=C3)C4=C(C)NC(=O)C(=C4)C#N)CC2
InChI
InChIKey=KLEKLDFUYOZELG-UHFFFAOYSA-N
InChI=1S/C27H30N4O4/c1-19-24(15-21(16-28)27(33)29-19)20-7-9-23(10-8-20)35-18-22(32)17-30-11-13-31(14-12-30)25-5-3-4-6-26(25)34-2/h3-10,15,22,32H,11-14,17-18H2,1-2H3,(H,29,33)
| Molecular Formula | C27H30N4O4 |
| Molecular Weight | 474.5515 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Saterinone, a dual-action drug combines both alpha-1 blocking vasodilatory property and phosphodiesterase III (PDE III) inhibition--mediated inotropism. PDE III inhibitors are well established in the acute intravenous treatment of patients with decompensated chronic congestive heart failure. Saterinone was demonstrated to be a safe and potent drug on short-term application without major changes in myocardial oxygen consumption. Saterinone was studied in phase II trials in Germany for the treatment of heart failure. However, the development of this drug has been discontinued.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacokinetics and hemodynamic effects of the phosphodiesterase III inhibitor saterinone in patients with chronic heart failure. | 2003-10 |
|
| Positive inotropic and vasodilatory actions of saterinone in vivo. | 1988-09 |
|
| Pharmacological properties of the positive inotropic and alpha 1-adrenoceptor blocking agent saterinone. | 1988-09 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14559131
Saterinone was given by intravenous infusion for 24 hours at a rate of 1.5 microg/kg per min
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:16:35 GMT 2025
by
admin
on
Wed Apr 02 09:16:35 GMT 2025
|
| Record UNII |
W4P85FO7GS
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C744
Created by
admin on Wed Apr 02 09:16:35 GMT 2025 , Edited by admin on Wed Apr 02 09:16:35 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C058572
Created by
admin on Wed Apr 02 09:16:35 GMT 2025 , Edited by admin on Wed Apr 02 09:16:35 GMT 2025
|
PRIMARY | |||
|
100000084099
Created by
admin on Wed Apr 02 09:16:35 GMT 2025 , Edited by admin on Wed Apr 02 09:16:35 GMT 2025
|
PRIMARY | |||
|
W4P85FO7GS
Created by
admin on Wed Apr 02 09:16:35 GMT 2025 , Edited by admin on Wed Apr 02 09:16:35 GMT 2025
|
PRIMARY | |||
|
65874
Created by
admin on Wed Apr 02 09:16:35 GMT 2025 , Edited by admin on Wed Apr 02 09:16:35 GMT 2025
|
PRIMARY | |||
|
102669-89-6
Created by
admin on Wed Apr 02 09:16:35 GMT 2025 , Edited by admin on Wed Apr 02 09:16:35 GMT 2025
|
PRIMARY | |||
|
CHEMBL2030222
Created by
admin on Wed Apr 02 09:16:35 GMT 2025 , Edited by admin on Wed Apr 02 09:16:35 GMT 2025
|
PRIMARY | |||
|
C74348
Created by
admin on Wed Apr 02 09:16:35 GMT 2025 , Edited by admin on Wed Apr 02 09:16:35 GMT 2025
|
PRIMARY | |||
|
DTXSID30883106
Created by
admin on Wed Apr 02 09:16:35 GMT 2025 , Edited by admin on Wed Apr 02 09:16:35 GMT 2025
|
PRIMARY | |||
|
SUB10457MIG
Created by
admin on Wed Apr 02 09:16:35 GMT 2025 , Edited by admin on Wed Apr 02 09:16:35 GMT 2025
|
PRIMARY | |||
|
5997
Created by
admin on Wed Apr 02 09:16:35 GMT 2025 , Edited by admin on Wed Apr 02 09:16:35 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |